For research use only. Not for therapeutic Use.
Benzyl Nicotinate, also known as Rubriment and Pycaril, is a GPR109A receptor agonist and GPR109B receptor agonist used as a rubefacient.
| Catalog Number | R036289 |
| CAS Number | 94-44-0 |
| Synonyms | Rubriment; Pyridine-3-carboxylic Acid Benzyl Ester; Niacin Benzyl Ester; Benzyl Pyridine-3-carboxylate; Benzyl Ester Nicotinic Acid; Phenylmethyl Ester 3-Pyridinecarboxylic Acid; |
| Molecular Formula | C13H11NO2 |
| Purity | ≥95% |
| Target | GPR109A/GPR109B Receptor Agonist |
| Storage | Store at RT |
| IUPAC Name | benzyl pyridine-3-carboxylate |
| InChI | InChI=1S/C13H11NO2/c15-13(12-7-4-8-14-9-12)16-10-11-5-2-1-3-6-11/h1-9H,10H2 |
| InChIKey | KVYGGMBOZFWZBQ-UHFFFAOYSA-N |
| SMILES | C1=CC=C(C=C1)COC(=O)C2=CN=CC=C2 |
| Reference | </br>1:Degradation kinetics of benzyl nicotinate in aqueous solution. Mbah CJ.Indian J Pharm Sci. 2010 Jan;72(1):46-9. doi: 10.4103/0250-474X.62238. PMID: 20582189 Free PMC Article</br>2:Influence of nanosized delivery systems with benzyl nicotinate and penetration enhancers on skin oxygenation. Abramović Z, Sustarsic U, Teskac K, Sentjurc M, Kristl J.Int J Pharm. 2008 Jul 9;359(1-2):220-7. doi: 10.1016/j.ijpharm.2008.03.014. Epub 2008 Mar 22. PMID: 18472233 </br>3:Kinetics of blood flow after topical application of benzyl nicotinate on different anatomic sites. Jacobi U, Kaiser M, Sterry W, Lademann J.Arch Dermatol Res. 2006 Nov;298(6):291-300. Epub 2006 Sep 12. PMID: 16967307 </br>4:Comparison of blood flow to the cutaneous temperature and redness after topical application of benzyl nicotinate. Jacobi U, Kaiser M, Koscielny J, Schütz R, Meinke M, Sterry W, Lademann J.J Biomed Opt. 2006 Jan-Feb;11(1):014025. PMID: 16526902 </br>5:Skin oxygenation after topical application of liposome-entrapped benzyl nicotinate as measured by EPR oximetry in vivo: influence of composition and size. Kristl J, Abramović Z, Sentjurc M.AAPS PharmSci. 2003;5(1):E2. PMID: 12713274 Free PMC Article</br>6:Improved skin oxygenation after benzyl nicotinate application in different carriers as measured by EPR oximetry in vivo. Krzic M, Sentjurc M, Kristl J.J Control Release. 2001 Jan 29;70(1-2):203-11. PMID: 11166420 </br>7:Effect of 4-(4/’-chlorobenzyloxy)benzyl nicotinate (KCD-232) on cholesterol metabolism in rats. Okada K, Yagasaki K, Mochizuki T, Takagi K, Irikura T.Biochem Pharmacol. 1985 Sep 15;34(18):3361-7. PMID: 4038342 </br>8:[Experimental nephrotic hyperlipidemia induced in rats by daunorubicin and effects of KCD-232[4-(4/’-chlorobenzyloxy)benzyl nicotinate] on lipid metabolism]. Okada K, Mochizuki T, Itaroku K, Takagi K, Irikura T.Nihon Yakurigaku Zasshi. 1985 May;85(5):347-56. Japanese. PMID: 4029807 </br>9:Effect of 4-(4/’-chlorobenzyloxy)benzyl nicotinate (KCD-232) on triglyceride and fatty acid metabolism in rats. Yagasaki K, Okada K, Mochizuki T, Takagi K, Irikura T.Biochem Pharmacol. 1984 Oct 15;33(20):3151-63. PMID: 6548383 </br>10:[Effects of 4-(4/’-chlorobenzyloxy) benzyl nicotinate (KCD-232) on lipid metabolism in rats and mice]. Okada K, Mochizuki T, Shinohara Y, Takahashi S, Takagi K, Irikura T.Nihon Yakurigaku Zasshi. 1984 Apr;83(4):331-43. Japanese. PMID: 6745812 |
